University Hospital Golnik

Golnik, Slovenia

University Hospital Golnik

Golnik, Slovenia
SEARCH FILTERS
Time filter
Source Type

Knez L.,University Hospital Golnik | Kosnik M.,University Hospital Golnik | Ovcaricek T.,University of Maribor | Sadikov A.,University of Ljubljana | And 3 more authors.
Journal of Cancer Research and Clinical Oncology | Year: 2012

Purpose: Multiple drug resistance limits the efficacy of numerous cytotoxic drugs used in the treatment of small cell lung cancer (SCLC). The drug efflux protein ATP-binding cassette transporter B1 (ABCB1) has an important role in this process, and its gene variability may affect chemotherapy outcomes. Patients and methods: This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy. To determine the ABCB1 genotype, allelic speciWc TaqMan® probes were used in a RT-PCR. Results: Patients carrying the G2677T/A TT + TA + AA genotypes (24 %) or the C3435T CT + TT genotypes (72 %) or the 2677T/A-3435T haplotype (40 %) had a longer PFS (Cox regression, P = 0.052, 0.037 and 0.037, respectively); these associations persisted also in multivariate analyses (Cox regression, P = 0.028, 0.037 and 0.030, respectively). Moreover, patients with the C3435T CT + TT genotypes had a longer OS both in univariate and multivariate analysis (Cox regression, P = 0.022 and 0.028, respectively). A trend toward longer OS was noted for the 2677T/A-3435T haplotype (Cox regression, P = 0.051), but its independent value was not confirmed (Cox regression, P = 0.071). Conclusions: Our study reported a possible predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype for longer PFS and OS in Caucasian SCLC patients treated with chemotherapy. However, to be implemented into routine clinical practice, ABCB1 polymorphisms require further validation. © Springer-Verlag 2012.


Gelbrich G.,University of Leipzig | Edelmann F.,University of Gottingen | Inkrot S.,Charité - Medical University of Berlin | Lainscak M.,Charité - Medical University of Berlin | And 9 more authors.
International Journal of Cardiology | Year: 2012

Background: Guideline-recommended beta-blocker (BB) target doses for patients with chronic heart failure can often not be reached. This secondary analysis of the CIBIS-ELD trial was carried out to better understand reasons for not achieving target doses. Methods: Changes in heart rate (HR) and other parameters during a 12-week up-titration period in 302 BB naïve patients were evaluated in the subgroups achieving 12.5, 25, 50, and 100% of the target dose (groups 1, 2, 3, and 4, respectively). Results: Achieved doses predominantly depended on baseline HR (means 68, 74, 76, and 84 bpm in groups 1-4, respectively, Pb0.001). HR was consistently reduced with each dose level to 65, 63, and 62 bpm in groups 1-3 and to 71 bpm in group 4 (Pb0.001). When adjusted for baseline, HR reduction achieved in group 3 was better than in group 4 (difference -5.4 bpm, Pb0.05). More patients in groups 3/4 than in groups 1/2 improved in NYHA class (P=0.01). NTproBNP increased by 38% in group 4 (Pb0.01) but not in the others (Pb0.05 between groups). Changes in blood pressure, six-minute walk distance and self-rated health were comparable in all groups. Conclusions: The desired effect of HR reduction appears to be a predominant limitation for BB up-titration. Vice versa, achieving the target dose may be a sign of insufficient response rather than successful treatment. In view of these results and the well-known importance of HR for survival, not target doses, but HR control should be given priority in BB treatment for heart failure. © 2010 Elsevier Ireland Ltd. All rights reserved.


PubMed | University Hospital Golnik
Type: Journal Article | Journal: Journal of cancer research and clinical oncology | Year: 2012

Multiple drug resistance limits the efficacy of numerous cytotoxic drugs used in the treatment of small cell lung cancer (SCLC). The drug efflux protein ATP-binding cassette transporter B1 (ABCB1) has an important role in this process, and its gene variability may affect chemotherapy outcomes.This study aimed to evaluate the associations between ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype with progression-free survival (PFS) and overall survival (OS) in 177 SCLC patients treated with cisplatin-etoposide or cyclophosphamide-epirubicin-vincristine chemotherapy. To determine the ABCB1 genotype, allelic specific TaqMan() probes were used in a RT-PCR .Patients carrying the G2677T/A TT+TA+AA genotypes (24%) or the C3435T CT+TT genotypes (72%) or the 2677T/A-3435T haplotype (40%) had a longer PFS (Cox regression, P=0.052, 0.037 and 0.037, respectively); these associations persisted also in multivariate analyses (Cox regression, P=0.028, 0.037 and 0.030, respectively). Moreover, patients with the C3435T CT+TT genotypes had a longer OS both in univariate and multivariate analysis (Cox regression, P=0.022 and 0.028, respectively). A trend toward longer OS was noted for the 2677T/A-3435T haplotype (Cox regression, P=0.051), but its independent value was not confirmed (Cox regression, P=0.071).Our study reported a possible predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype for longer PFS and OS in Caucasian SCLC patients treated with chemotherapy. However, to be implemented into routine clinical practice, ABCB1 polymorphisms require further validation.

Loading University Hospital Golnik collaborators
Loading University Hospital Golnik collaborators